Ako Ishihara
Overview
Explore the profile of Ako Ishihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lauterbach A, Wallace R, Alpar A, Refvik K, Reda J, Ishihara A, et al.
NPJ Regen Med
. 2023 Nov;
8(1):62.
PMID: 37919358
No abstract available.
2.
Lauterbach A, Wallace R, Alpar A, Refvik K, Reda J, Ishihara A, et al.
NPJ Regen Med
. 2023 Sep;
8(1):49.
PMID: 37696884
Non-healing wounds have a negative impact on quality of life and account for many cases of amputation and even early death among patients. Diabetic patients are the predominate population affected...
3.
Yuba E, Budina E, Katsumata K, Ishihara A, Mansurov A, Alpar A, et al.
Arthritis Rheumatol
. 2020 Nov;
73(5):769-778.
PMID: 33169522
Objective: Rheumatoid arthritis (RA) is a major autoimmune disease that causes synovitis and joint damage. Although clinical trials have been performed using interleukin-10 (IL-10), an antiinflammatory cytokine, as a potential...
4.
Ishihara A, Ishihara J, Watkins E, Tremain A, Nguyen M, Solanki A, et al.
Nat Biomed Eng
. 2020 Oct;
4(11):1117.
PMID: 33093659
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
5.
Ishihara A, Ishihara J, Watkins E, Tremain A, Nguyen M, Solanki A, et al.
Nat Biomed Eng
. 2020 Oct;
5(5):387-398.
PMID: 33046864
Interleukin-4 (IL-4) suppresses the development of multiple sclerosis in a murine model of experimental autoimmune encephalomyelitis (EAE). Here, we show that, in mice with EAE, the accumulation and persistence in...
6.
Mansurov A, Ishihara J, Hosseinchi P, Potin L, Marchell T, Ishihara A, et al.
Nat Biomed Eng
. 2020 Apr;
4(5):531-543.
PMID: 32284554
Checkpoint-inhibitor (CPI) immunotherapy has achieved remarkable clinical success, yet its efficacy in 'immunologically cold' tumours has been modest. Interleukin-12 (IL-12) is a powerful cytokine that activates the innate and adaptive...
7.
Katsumata K, Ishihara J, Fukunaga K, Ishihara A, Yuba E, Budina E, et al.
Arthritis Res Ther
. 2019 Dec;
21(1):298.
PMID: 31870429
Background: Although disease in a majority of rheumatoid arthritis (RA) patients is often initially limited to one or a few joints, currently approved medications including anti-tumor necrosis factor-α antibody (α-TNF)...
8.
Williford J, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell T, et al.
Sci Adv
. 2019 Dec;
5(12):eaay1357.
PMID: 31844672
Although a clinical breakthrough for cancer treatment, it remains that a minority of patients respond to checkpoint inhibitor (CPI) immunotherapy. The composition of tumor-infiltrating immune cells has been identified as...
9.
Katsumata K, Ishihara J, Mansurov A, Ishihara A, Raczy M, Yuba E, et al.
Sci Adv
. 2019 Nov;
5(11):eaay1971.
PMID: 31723606
Enhancing the therapeutic efficacy of drugs for inflammatory diseases is of high demand. One possible approach is targeting drugs to the extracellular matrix of the inflamed area. Here, we target...
10.
Sasaki K, Ishihara J, Ishihara A, Miura R, Mansurov A, Fukunaga K, et al.
Sci Adv
. 2019 Aug;
5(8):eaaw6081.
PMID: 31453327
Serum albumin (SA) is used as a carrier to deliver cytotoxic agents to tumors via passive targeting. To further improve SA's tumor targeting capacity, we sought to develop an approach...